Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A child with severe juvenile dermatomyositis treated with ruxolitinib.

Authors: Hanna Kim; Fatima Gunter-Rahman; John A McGrath; Esther Lee; Adriana A de Jesus; Ira N Targoff; Yan Huang; Terrance P O'Hanlon; Wanxia L Tsai; Massimo Gadina; Frederick W Miller; Raphaela Goldbach-Mansky; Lisa G Rider
Journal: Arthritis Res Ther Date: 2020-04-06 Impact factor: 5.156

5. Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome

Authors: Marcelo Iastrebner; Joaquín Castro; Edgardo García Espina; Carolina Lettieri; Silvio Payaslian; María Celia Cuesta; Pablo Gutiérrez Fernández; Araceli Mandrile; Angela Paola Contreras; Sebastián Gervasoni; Gabriel Verde; Cayetano Galetti; Estefanía Minoldo; Vanesa Caruso
Journal: Rev Fac Cien Med Univ Nac Cordoba Date: 2021-09-07

Review 6. Cardiovascular Abnormalities in Juvenile Dermatomyositis: A Scoping Review for the Clinical Rheumatologists.

Authors: Sanjib Mondal; Prabal Barman; Pandiarajan Vignesh
Journal: Front Med (Lausanne) Date: 2022-06-24

Review 7. Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature.

Authors: Kareem G Elhage; Raymond Zhao; Mio Nakamura
Journal: Clin Cosmet Investig Dermatol Date: 2022-09-08

A child with severe juvenile dermatomyositis treated with ruxolitinib.

Review 1. The relationship between JAK2(V617F) mutation and dermatomyositis-a case report and literature review.

Review 2. Treatment of Calcinosis in Juvenile Dermatomyositis.

Review 3. [Juvenile dermatomyositis-what's new?]

4. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.

5. Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome

Review 6. Cardiovascular Abnormalities in Juvenile Dermatomyositis: A Scoping Review for the Clinical Rheumatologists.

Review 7. Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature.

Review 8. Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy.

Review 9. New insights into the treatment of myositis.

Review 10. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology.